Close Menu

A news piece in this week's Science reports that ECell International (ESI), a Singapore-based company, is stopping research work on human embryonic stem cells due to increasing lack of investor interest. The time lag from lab to clinic is too long, investors say, but several companies, including Geron and ACT, are not giving up, claiming they have products in the pipeline.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.